These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 31115908)

  • 21. Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors.
    Zhao X; Suryawanshi S; Hruska M; Feng Y; Wang X; Shen J; Vezina HE; McHenry MB; Waxman IM; Achanta A; Bello A; Roy A; Agrawal S
    Ann Oncol; 2017 Aug; 28(8):2002-2008. PubMed ID: 28520840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer.
    Basak EA; Koolen SLW; Hurkmans DP; Schreurs MWJ; Bins S; Oomen-de Hoop E; Wijkhuijs AJM; Besten ID; Sleijfer S; Debets R; van der Veldt AAM; Aerts JGJV; Mathijssen RHJ
    Eur J Cancer; 2019 Mar; 109():12-20. PubMed ID: 30654225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA.
    John T; Sakai H; Ikeda S; Cheng Y; Kasahara K; Sato Y; Nakahara Y; Takeda M; Kaneda H; Zhang H; Maemondo M; Minato K; Hisada T; Misumi Y; Satouchi M; Hotta K; Li A; Oukessou A; Lu S
    Int J Clin Oncol; 2022 Apr; 27(4):695-706. PubMed ID: 35182247
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer.
    Okuma Y; Wakui H; Utsumi H; Sagawa Y; Hosomi Y; Kuwano K; Homma S
    Clin Lung Cancer; 2018 Sep; 19(5):410-417.e1. PubMed ID: 29859759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective.
    Bi Y; Liu J; Furmanski B; Zhao H; Yu J; Osgood C; Ward A; Keegan P; Booth BP; Rahman A; Wang Y
    Ann Oncol; 2019 Apr; 30(4):644-651. PubMed ID: 30715147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870).
    Lu S; Cheng Y; Zhou J; Wang M; Zhao J; Wang B; Chen G; Feng J; Ma Z; Wu L; Wang C; Ma K; Zhang S; Liang J; Song Y; Wang J; Wu YL; Li A; Huang Y; Chang J
    Ther Adv Med Oncol; 2022; 14():17588359221138380. PubMed ID: 36425873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of morphological characteristics assessed by CT scan in patients with non-small cell lung cancer treated with nivolumab.
    Minemura H; Moriya H; Imai H; Sugiyama T; Yamada Y; Higuchi M; Kaira K; Ozaki Y; Kanazawa K; Yokouchi H; Kasai T; Kaburagi T; Suzuki H; Minato K; Shibata Y
    Thorac Cancer; 2020 Dec; 11(12):3521-3527. PubMed ID: 33044045
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
    JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Multivariable Regression Model-based Nomogram for Estimating the Overall Survival of Patients Previously Treated With Nivolumab for Advanced Non-small-cell Lung Cancer.
    Tamiya A; Tamiya M; Go H; Inoue T; Kunimasa K; Nakahama K; Taniguchi Y; Shiroyama T; Isa SI; Nishino K; Kumagai T; Suzuki H; Hirashima T; Atagi S; Shintani A; Imamura F
    Anticancer Res; 2020 Aug; 40(8):4229-4236. PubMed ID: 32727749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preoperative nivolumab to evaluate pathological response in patients with stage I non-small cell lung cancer: a study protocol of phase II trial (POTENTIAL).
    Kagimoto A; Tsutani Y; Mimae T; Miyata Y; Ikeda N; Ito H; Maniwa Y; Suzuki K; Tsuboi M; Yoshimura K; Umemoto S; Okada M
    BMJ Open; 2021 Mar; 11(3):e043234. PubMed ID: 33737428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer.
    Grossi F; Genova C; Crinò L; Delmonte A; Turci D; Signorelli D; Passaro A; Soto Parra H; Catino A; Landi L; Gelsomino F; Tiseo M; Puppo G; Roila F; Ricciardi S; Tonini G; Cognetti F; Toschi L; Tassinari D; Scoppola A; Giannarelli D; Cortesi E
    Eur J Cancer; 2019 Dec; 123():72-80. PubMed ID: 31671314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Model-Based Dose Selection of Subcutaneous Nivolumab in Patients with Advanced Solid Tumors.
    Zhao Y; Sanghavi K; Roy A; Murthy B; Bello A; Aras U; Vezina H
    Clin Pharmacol Ther; 2024 Mar; 115(3):488-497. PubMed ID: 38115195
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative effectiveness of pembrolizumab vs. nivolumab in patients with recurrent or advanced NSCLC.
    Cui P; Li R; Huang Z; Wu Z; Tao H; Zhang S; Hu Y
    Sci Rep; 2020 Aug; 10(1):13160. PubMed ID: 32753702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Benefit-risk assessment of nivolumab 240 mg flat dose relative to 3 mg/kg Q2W regimen in Japanese patients with advanced cancers.
    Bei D; Osawa M; Uemura S; Ohno T; Gobburu J; Roy A; Hasegawa M
    Cancer Sci; 2020 Feb; 111(2):528-535. PubMed ID: 31773815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types.
    Zhao X; Shen J; Ivaturi V; Gopalakrishnan M; Feng Y; Schmidt BJ; Statkevich P; Goodman V; Gobburu J; Bello A; Roy A; Agrawal S
    Ann Oncol; 2020 Feb; 31(2):302-309. PubMed ID: 31959348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment and relapse of interstitial lung disease in nivolumab-treated patients with non-small cell lung cancer.
    Sata M; Sasaki S; Oikado K; Saito Y; Tominaga J; Sakai F; Kato T; Iwasawa T; Kenmotsu H; Kusumoto M; Baba T; Endo M; Fujiwara Y; Sugiura H; Yanagawa N; Ito Y; Sakamoto T; Ohe Y; Kuwano K
    Cancer Sci; 2021 Apr; 112(4):1506-1513. PubMed ID: 33125784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer.
    Hida T; Nishio M; Nogami N; Ohe Y; Nokihara H; Sakai H; Satouchi M; Nakagawa K; Takenoyama M; Isobe H; Fujita S; Tanaka H; Minato K; Takahashi T; Maemondo M; Takeda K; Saka H; Goto K; Atagi S; Hirashima T; Sumiyoshi N; Tamura T
    Cancer Sci; 2017 May; 108(5):1000-1006. PubMed ID: 28266091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non-Small Cell Lung Cancer.
    Fujimoto D; Sato Y; Uehara K; Ishida K; Fukuoka J; Morimoto T; Kawachi H; Mori R; Ito M; Teraoka S; Nagata K; Nakagawa A; Otsuka K; Imai Y; Tomii K
    J Thorac Oncol; 2018 Mar; 13(3):377-386. PubMed ID: 29233789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non-small Cell Lung Cancer.
    Inoue Y; Yoshimura K; Nishimoto K; Inui N; Karayama M; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Asada K; Uto T; Fujii M; Matsui T; Matsuura S; Hashimoto D; Toyoshima M; Kusagaya H; Matsuda H; Inami N; Kaida Y; Niwa M; Ito Y; Sugimura H; Suda T
    JAMA Netw Open; 2020 Sep; 3(9):e2011818. PubMed ID: 32955570
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.
    Gettinger S; Horn L; Jackman D; Spigel D; Antonia S; Hellmann M; Powderly J; Heist R; Sequist LV; Smith DC; Leming P; Geese WJ; Yoon D; Li A; Brahmer J
    J Clin Oncol; 2018 Jun; 36(17):1675-1684. PubMed ID: 29570421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.